PMID- 26507578
OWN - NLM
STAT- MEDLINE
DCOM- 20160613
LR  - 20151125
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 7
IP  - 10
DP  - 2015
TI  - The impact of dendritic cell-tumor fusion cells on cancer vaccines - past 
      progress and future strategies.
PG  - 1111-22
LID - 10.2217/imt.15.73 [doi]
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that can be used in 
      cancer vaccines. Thus, various strategies have been developed to deliver 
      tumor-associated antigens via DCs. One strategy includes administering DC-tumor 
      fusion cells (DC-tumor FCs) to induce antitumor immune responses in cancer 
      patients. However, clinical trials using this strategy have fallen short of 
      expectations. Several factors might limit the efficacy of these anticancer 
      vaccines. To induce efficient antitumor immune responses and enhance potential 
      clinical benefits, DC-tumor FC-based cancer vaccines require manipulations that 
      improve immunogenicity for both DCs and whole tumor cells. This review addresses 
      recent progress in improving clinical outcomes using DC-tumor FC-based cancer 
      vaccines.
FAU - Kajihara, Mikio
AU  - Kajihara M
AD  - Division of Gastroenterology & Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Takakura, Kazuki
AU  - Takakura K
AD  - Division of Gastroenterology & Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Ohkusa, Toshifumi
AU  - Ohkusa T
AD  - Division of Gastroenterology & Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Koido, Shigeo
AU  - Koido S
AD  - Division of Gastroenterology & Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20151028
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - *Antigen Presentation
MH  - Antigens, Neoplasm/immunology/*therapeutic use
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Cell Fusion/trends
MH  - Dendritic Cells/*immunology
MH  - Humans
OTO - NOTNLM
OT  - cancer vaccines
OT  - dendritic cell
OT  - dendritic cell-tumor fusion cell
OT  - immunogenicity
OT  - whole tumor cell
EDAT- 2015/10/29 06:00
MHDA- 2016/06/14 06:00
CRDT- 2015/10/29 06:00
PHST- 2015/10/29 06:00 [entrez]
PHST- 2015/10/29 06:00 [pubmed]
PHST- 2016/06/14 06:00 [medline]
AID - 10.2217/imt.15.73 [doi]
PST - ppublish
SO  - Immunotherapy. 2015;7(10):1111-22. doi: 10.2217/imt.15.73. Epub 2015 Oct 28.